Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This drug is a **combination mouthwash formulation** containing lidocaine (a local anesthetic), diphenhydramine (an antihistamine), aluminum hydroxide and magnesium hydroxide (antacids), and simethicone (an anti-foaming agent). It is often referred to as “magic mouthwash” or BMX mouthwash and is used primarily to treat **oral mucositis pain and discomfort** associated with cancer therapy, particularly radiotherapy and chemotherapy. The mechanism of action involves multiple targets: lidocaine blocks voltage-gated sodium channels to provide local anesthesia; diphenhydramine acts as an H1 antihistamine with local anesthetic properties; aluminum hydroxide and magnesium hydroxide neutralize oral acidity and provide mucosal coating; simethicone reduces surface tension and may help distribute the mixture and reduce foaming. The efficacy is primarily symptomatic, aiming to reduce pain and allow oral intake in patients with inflamed mucosa. These combinations are typically prepared by pharmacists and may be provided as a compounded prescription or via kits such as FIRST Mouthwash BLM[9][7][5][4][2].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on lidocaine + diphenhydramine + aluminum hydroxide + magnesium hydroxide + simethicone.